For immediate release

25 May 2017

ALLIANCE PHARMA PLC

('Alliance' or the 'Company')

Changes to interests of a significant shareholder

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder. In accordance with AIM rule 17, the following details are now notified:

(a) Identity of the significant shareholder: Aviva plc and its subsidiaries

(b) Date of disclosure: 24 May 2017

(c) Date of relevant change: 23 May 2017

(d) Price, amount and class: 18,286,806 ordinary shares of 1p each; price not disclosed

(e) Nature of transaction: sale of shares

(f) Nature and extent of significant shareholder's interest: direct and indirect interests

(g) Resultant shareholding: below 3%

In compliance with DTR5, a copy of the notification received from this investor is appended.

For further information:

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive

Andrew Franklin, Chief Financial Officer

Rob Bellhouse, Company Secretary

www.alliancepharma.co.uk

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Sophie Cowles

Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

Aviva plc published this content on 25 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 May 2017 14:30:13 UTC.

Original documenthttp://otp.investis.com/clients/uk/avivaplc/rns/regulatory-story.aspx?cid=759&newsid=877016

Public permalinkhttp://www.publicnow.com/view/7B09C0B934FCACF73CF14FE92D45B76D99E1C5BD